Chemomab Therapeutics is a clinical-stage biotech company discovering and developing innovative therapeutics for conditions with high unmet need that involve Inflammation and fibrosis
Translating novel biological insights into long-term transformative treatments
Drug discovery and development that are built on a deep understanding of central fibrotic mediators and pathways
Committed to improve the quality of life of patients suffering from seriously debilitating and life-threatening diseases
Innovation & Discovery
Chemomab discovered the key role of the soluble chemokine CCL24 in promoting liver, skin and lung fibrosis.
Fibrosis-related diseases are a significant unmet need that dramatically affect patients health and quality of life.
Damaged tissue repairs itself through a sequence of controlled inflammatory and fibrotic processes. However, uncontrolled healing processes can create a vicious cycle of inflammation and fibrosis – an excessive, sustained, chronic inflammatory response that activates fibroblasts, and replaces functional tissue with fibrous scar tissue.
CCL24 - a Key Player
Regulating CCL24 is key to halting fibrosis-related conditions
Chemomab discovered that the soluble chemokine CCL24 plays a key role in promoting inflammation and fibrosis via a dual pathway. CCL24 promotes both the recruitment of immune cells to the damaged tissue and supports its polarization to create a pro-fibrotic environment. In parallel, CCL24 directly activates tissue fibroblasts, enhances their transition into myofibroblasts and induces the uncontrolled production of extracellular matrix.
CM-101 Therapeutic Platform
Pioneering innovation to treat fibrosis-related diseases.
Chemomab’s lead compound, CM-101, currently tested in phase II clinical studies, is a first-in-class humanized monoclonal antibody designed to bind to and block CCL24 activity.
CM-101 interferes with the main pathologies that promote fibrosis and inflammation. It is highly effective in ameliorating fibrosis, as shown across multiple in vivo, in vitro and ex vivo studies, including experimental models of liver, skin and lung fibrosis. CM-101 is currently under clinical development for Primary Sclerosing Cholangitis , Systemic Sclerosis and Non-Alcoholic Steatohepatitis.
IV — Intravenous
SC — Subcutaneous
Patient Data Presented at 2023 EULAR Congress Highlights How Serum CCL24 Levels Can Predict Vascular and Fibrotic Complications of Systemic Sclerosis
Chemomab Therapeutics to Participate in Upcoming Scientific Conferences
Chemomab Therapeutics Announces First Quarter 2023 Financial Results and Provides a Corporate Update
Chemomab Therapeutics to Present at 2023 Aegis Virtual Conference